Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures.
The previous two studies in dogs related to Panion’s gene therapy product documented the safety of the treatment and procedures. They were both conducted in the University of Copenhagen under the lead of associate professor David Woldbye, who is one of the scientific founders of the innovation and a member of Panion’s advisory board.
This Friday, 8.th of March 2019, the head of LIVS and lead investigator, Dominic Marino, held a technical meeting with David Woldbye in Copenhagen to ensure full transfer of knowledge and technical procedures. The two highly competent persons from each their field – Dr. Marino as an experienced veterinary neurosurgeon, and Dr. Woldbye as the scientific expert and human medical doctor – exchanged experiences to secure the optimal way to progress the clinical study successfully.
The CEO of Panion, veterinarian Anja Holm, attended the meeting: “I am very grateful that Dr. Marino travels from New York to Copenhagen to secure that all information is captured directly face-to-face. It shows his dedication to the project and his belief in the scientific foundation and prospect of this new treatment for the dogs.”